BG108518A - Crystalline forms vi and vii of atorvastatin calcium - Google Patents

Crystalline forms vi and vii of atorvastatin calcium

Info

Publication number
BG108518A
BG108518A BG108518A BG10851804A BG108518A BG 108518 A BG108518 A BG 108518A BG 108518 A BG108518 A BG 108518A BG 10851804 A BG10851804 A BG 10851804A BG 108518 A BG108518 A BG 108518A
Authority
BG
Bulgaria
Prior art keywords
vii
crystalline forms
atorvastatin calcium
methods
relates
Prior art date
Application number
BG108518A
Other languages
Bulgarian (bg)
English (en)
Inventor
Satynarajana M. Reddy
Chakilam Nagaraju
Gudipati Shrinivasulu
Katakam Sinivas
Sagyam R. Reddy
Original Assignee
Dr.Reddy's Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr.Reddy's Laboratories Ltd. filed Critical Dr.Reddy's Laboratories Ltd.
Publication of BG108518A publication Critical patent/BG108518A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG108518A 2001-07-30 2004-01-09 Crystalline forms vi and vii of atorvastatin calcium BG108518A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN620MA2001 2001-07-30
PCT/US2002/000431 WO2003011826A1 (fr) 2001-07-30 2002-01-07 Formes cristallines vi et vii de calcium d'atorvastatine

Publications (1)

Publication Number Publication Date
BG108518A true BG108518A (en) 2004-08-31

Family

ID=35160889

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108518A BG108518A (en) 2001-07-30 2004-01-09 Crystalline forms vi and vii of atorvastatin calcium

Country Status (19)

Country Link
EP (2) EP1414796A1 (fr)
JP (1) JP2005500351A (fr)
KR (1) KR20040019043A (fr)
CN (1) CN100471836C (fr)
AU (1) AU2002255479B2 (fr)
BG (1) BG108518A (fr)
BR (1) BR0211488A (fr)
CA (1) CA2454500C (fr)
CZ (1) CZ2004126A3 (fr)
EE (1) EE200400048A (fr)
HR (1) HRP20040077A2 (fr)
IL (2) IL159626A0 (fr)
MX (1) MXPA04000889A (fr)
NO (1) NO20040390L (fr)
NZ (1) NZ530785A (fr)
PL (1) PL368647A1 (fr)
RU (1) RU2304139C2 (fr)
WO (1) WO2003011826A1 (fr)
ZA (1) ZA200400573B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL155734A0 (en) * 2000-11-03 2003-11-23 Teve Pharmaceutical Ind Ltd Atorvastatin hemi-calcium form vii
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CZ20032019A3 (cs) * 2000-12-27 2003-10-15 Ciba Specialty Chemicals Holding Inc. Krystalické formy Atorvastatinu
PL372303A1 (en) * 2002-02-15 2005-07-11 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
MXPA04007995A (es) 2002-02-19 2004-11-26 Teva Pharma Desolvatacion de solvatos de hemicalcio de atorvastatina.
EP1424324A1 (fr) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Forme cristalline F de calcium d'atorvastatine
AU2003297594A1 (en) * 2002-11-28 2004-06-23 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
WO2005090301A1 (fr) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Forme cristalline d'hemi-calcium d'atorvastatine
EP1577297A1 (fr) 2004-03-17 2005-09-21 Ranbaxy Laboratories, Ltd. Procede de production d'atorvastatine calcique sous forme amorphe
JP5000502B2 (ja) * 2004-07-16 2012-08-15 レツク・フアーマシユーテイカルズ・デー・デー アトルバスタチンカルシウムの酸化分解生成物
CA2672554C (fr) 2004-07-20 2012-01-03 Warner-Lambert Company Llc Nouvelles formes de [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(isopropyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoatede calcium (2:1)
CN101124230A (zh) * 2004-09-28 2008-02-13 特瓦制药工业有限公司 制备基本无杂质的阿托伐他汀钙形式的方法
AU2005298383A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
WO2006048894A1 (fr) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication
BRPI0610344A2 (pt) 2005-12-13 2016-11-29 Teva Pharma forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal
EP2185527A2 (fr) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Nouveau polymorphe d'atorvastatine calcium et son utilisation pour la préparation d'atorvastatine calcium amorphe
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
CN108157405B (zh) * 2018-02-06 2020-10-02 上海应用技术大学 一种灭蟑螂饵剂及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL128862A (en) 1995-07-17 2007-12-03 Warner Lambert Co [R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5929156A (en) 1997-05-02 1999-07-27 J.M. Huber Corporation Silica product for use in elastomers
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
PT1235799E (pt) 1999-11-17 2005-05-31 Teva Pharma Forma polimorfica de atorvastatina-calcio
IL155734A0 (en) * 2000-11-03 2003-11-23 Teve Pharmaceutical Ind Ltd Atorvastatin hemi-calcium form vii
AU3289102A (en) * 2000-11-16 2002-06-11 Teva Pharma Hydrolysis of (R(R*,R*))-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino) carbonyl)-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CZ20032019A3 (cs) * 2000-12-27 2003-10-15 Ciba Specialty Chemicals Holding Inc. Krystalické formy Atorvastatinu
WO2002057229A1 (fr) * 2001-01-19 2002-07-25 Biocon India Limited FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)

Also Published As

Publication number Publication date
RU2004103470A (ru) 2005-06-20
CN1537098A (zh) 2004-10-13
CZ2004126A3 (cs) 2004-12-15
BR0211488A (pt) 2004-08-17
EP1414796A1 (fr) 2004-05-06
MXPA04000889A (es) 2004-06-03
AU2002255479B2 (en) 2008-09-11
IL159626A (en) 2013-04-30
EP2292600A1 (fr) 2011-03-09
ZA200400573B (en) 2005-05-11
RU2304139C2 (ru) 2007-08-10
IL159626A0 (en) 2004-06-01
CA2454500A1 (fr) 2003-02-13
HRP20040077A2 (en) 2004-06-30
CA2454500C (fr) 2009-11-10
KR20040019043A (ko) 2004-03-04
NZ530785A (en) 2005-10-28
CN100471836C (zh) 2009-03-25
WO2003011826A1 (fr) 2003-02-13
NO20040390L (no) 2004-01-29
PL368647A1 (en) 2005-04-04
EE200400048A (et) 2004-04-15
JP2005500351A (ja) 2005-01-06

Similar Documents

Publication Publication Date Title
BG108518A (en) Crystalline forms vi and vii of atorvastatin calcium
HRP20031039A2 (en) Crystalline forms of 'r-(r*,r*)^-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl^-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
YU36802A (sh) Postupak za dobijanje amorfnog atorvastatina
EP1783113A3 (fr) Forme cristalline VII d'hémi-calcium d'atorvastatine
BG102186A (en) Crystalline form iii of hemicalcium salts of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta -dyhydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h -ppyrol-1-heptane acid (atorvastatin)
HRP960339B1 (en) Crystalline /r- (r*, r*)/-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-/(phenylamino) carbonyl/-1h-pyrrole-1-heptanoic acid hemi calcium salt
HK1018054A1 (en) Novel process for the production of amorphous -[r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HUP0402590A3 (en) Method of manufacturing an amorphous form of the hemi-calcium salt of (3r,5r)7-3-phenyl-4-phenylcarbomoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin)
PL370061A1 (en) Crystalline (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-heptanoic acid calcium salt (2:1)
CA2508871A1 (fr) Forme cristalline f de sel d'hemi-calcium d'astorvastatine
IL173651A0 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
PL349307A1 (en) Novel crystalline form of semi-calcium [r-(r ,r)]-2-(4-fluorophenyl)-beta, dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl)-1h-pyrrole-1-heptanic salt (athorovastatin), method of obtaining same, pharmacological composition containing such salt and medical application thereof
CA2522899A1 (fr) Formes cristallines de sel hemicalcique d'acide [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique (2:1)(atorvastatine)
ZA200303974B (en) Hydrolysis of [R(R*,R*)]-2-(4-Fluorophenyl)-b,D-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic acid esters with calcium hydroxide.
IS7019A (is) Kristallaform af 'R-(R*,R*)!-2-(4-flúorfenýl)-beta, delta-díhýdroxý-5-(1-metýletýl)-3-fenýl-4-'fenýlamínó)karbónýl!-1H-pýrról-1-heptansýru kalsíum salt (2:1) (atorvastatín)
AU2001234058A1 (en) Form v crystalline (r-(r*,r*))-2-(4-fluorophenyl)-ss,$g(d)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1- heptanoic acid hemi calcium salt. (atorvastatin)